Virax Biolabs to Present at 19th World Immune Regulation Meeting
Rhea-AI Summary
Virax Biolabs (Nasdaq: VRAX) has announced its participation in the prestigious 19th World Immune Regulation Meeting (WIRM) taking place March 12-15, 2025, in Davos, Switzerland. The company's Chief Operating Officer, Dr. Nigel McCracken, will deliver a presentation titled 'Evaluation of T cell dysfunction in post acute infection syndromes' on March 12, 2025, at 20:00 in Foyer A1 of The Congress Center.
The biotechnology company, focused on viral disease diagnosis and immune response detection, will also showcase its immune profiling products at Booth 116. Management will be available to engage with research organizations and potential customers during the event.
WIRM 2025 is set to bring together approximately 600 scientists and clinicians worldwide, featuring scientific lectures, networking opportunities, and a poster exhibition in Davos.
Positive
- None.
Negative
- None.
News Market Reaction – VRAX
In the trading session that priced this news, VRAX declined 7.48%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentation Details:
Title: Evaluation of T cell dysfunction in post acute infection syndromes
Presenter: Dr. Nigel McCracken, Chief Operating Officer at Virax Biolabs
Date: Wednesday, March 12, 2025, at 20:00
Location: Foyer A1, The Congress Center, Davos,
Additionally, the Company will be showcasing its portfolio of immune profiling products for research use at Booth 116, and management will be available for discussions with research organizations and potential customers.
WIRM 2025 is an esteemed conference where approximately 600 scientists and clinicians from around the globe gather to discuss the latest advancements in immunology. This four-day event combines top-tier scientific lectures, informal networking, and a poster exhibition, all set against the stunning backdrop of
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
For more information, please visit www.viraxbiolabs.com.
Investor Relations Contact:
Russo Partners, LLC
Nic Johnson
12 West 27th Street
4th Floor
M: 303-482-6405
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-to-present-at-19th-world-immune-regulation-meeting-302392440.html
SOURCE Virax Biolabs